Natriumjodid (I-123) Curium Netherlands (Sodium Iodide (123 I))

Sodium Iodide (I-123), the active ingredient in Natriumjodid (I-123) Curium Netherlands, is a radiopharmaceutical presented as a sterile solution for intravenous use. It is employed for diagnostic imaging of thyroid function and anatomy in patients undergoing thyroid scintigraphy and related evaluations.

GNH USA supplies Natriumjodid (I-123) Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Sodium Iodide (I-123) is used in nuclear medicine for thyroid imaging, allowing assessment of thyroid function and structure.

- Thyroid scintigraphy: provides functional images of thyroid tissue to evaluate uptake patterns. - Hyperthyroidism evaluation: helps differentiate causes of excess thyroid hormone production. - Thyroid nodule assessment: assists in characterising nodules as benign or malignant based on iodine uptake.

Adverse reactions may occur following administration of Sodium Iodide (I-123).

Common Side Effects: - Mild nausea - Transient flushing - Headache - Injection‑site discomfort

Serious or Rare Side Effects: - Allergic reaction, including anaphylaxis - Radiation‑induced thyroiditis - Severe hypotension

Use of Sodium Iodide (I-123) requires careful consideration of patient‑specific factors and handling requirements.

- Pregnancy: administer only if the diagnostic benefit outweighs potential fetal radiation risk. - Breastfeeding: consider temporary cessation of nursing or use of expressed milk. - Baseline thyroid function: assess uptake baseline before tracer administration. - Concurrent iodine therapy: avoid high‑dose iodide within 24 hours of the procedure. - Radiation safety: follow institutional protocols for shielding, waste disposal, and personnel monitoring. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sodium Iodide (I-123) may interact with other agents that affect iodine handling or thyroid physiology.

Major Interactions (Avoid): - High‑dose iodide therapy: reduces tracer uptake and compromises image quality. - Thyroid blocking agents (e.g., perchlorate): prevent tracer accumulation in thyroid tissue.

Moderate Interactions (Monitor Closely): - Antithyroid drugs (methimazole, propylthiouracil): may alter iodine uptake dynamics. - Lithium therapy: can increase thyroid retention of the tracer. - Recent contrast agents (within 24 h): may interfere with imaging results.